Dirk de Ruysscher (D.K.M.)

Hattu, D., Taasti, V. T., Emans, D., Velders, M., van der Stoep, J., Vullings, A., van den Bosch, M., Buck, J., van der Salm, A., van Loon, J., Ruysscher, D. D., & Canters, R. (2025). Effects of anatomical changes on dose and normal tissue complication probabilities and the benefit of replanning in photon and proton therapy of lung cancer patients. Radiotherapy and Oncology, 211, Article 111063. https://doi.org/10.1016/j.radonc.2025.111063

Xenophontos, E., Giaj Levra, N., Durieux, V., van Geffen, W. H., Grisay, G., De la Pinta Alonso, C., Arasanz, H., Prisciandaro, E., Ferrara, R., Derks, J., Von der Thusen, J., Dickhoff, C., Brandão, M., Faivre-Finn, C., Edwards, J., Ruysscher, D. D., Remon, J., Dingemans, A. M. C., & Berghmans, T. (2025). Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group. Lung Cancer, 207, Article 108671. https://doi.org/10.1016/j.lungcan.2025.108671

Taasti, V. T., Hattu, D., Berbée, M., de Ruysscher, D., & Canters, R. (2025). Dose accumulation over the treatment course including setup and range uncertainty for proton therapy of esophageal and lung cancer patients. Medical Physics, 52(8), Article e18037. https://doi.org/10.1002/mp.18037

Cooke, S. A., Belderbos, J. S. A., Stam, B., Reymen, B., Lambrecht, M., Fredberg Persson, G., Faivre-Finn, C., Dieleman, E. M. T., van Diessen, J., de Ruysscher, D., & Sonke, J. J. (2025). Esophageal Toxicity After Dose-Escalated Radiation Therapy for Stage II-III Non-Small Cell Lung Cancer: A Secondary Analysis of the Phase 2 Randomized ARTFORCE PET-Boost Trial. International Journal of Radiation Oncology Biology Physics, 122(5), 1227-1237. https://doi.org/10.1016/j.ijrobp.2025.03.001

Aguado-Flor, E., Reyes, V. M., Navarro, V., Mollà, M., Aguado-Barrera, M. E., Altabas, M., Azria, D., Baten, A., Bourgier, C., Bultijnck, R., Chang-Claude, J., De Santis, M. C., Dunning, A. M., Duran-Lozano, L., Elliott, R. M., Farcy Jacquet, M. P., Giandini, C., Giraldo, A., Green, S., ... Vanneste, B. (2025). Integrating genetic polymorphisms and clinical data to develop predictive models for skin toxicity in breast cancer radiation therapy. Breast, 82, Article 104506. https://doi.org/10.1016/j.breast.2025.104506

Huijs, J. W. J., Bortolot, M., Berghoff, A. S., Brastianos, P. K., Degens, J. H. R. J., De Ruysscher, D. K. M., Compter, A., & Hendriks, L. E. L. (2025). Screening for brain metastases in patients with advanced non-small cell lung cancer and an actionable genomic alteration: A structured literature review. Neuro-Oncology Practice, 12(4), 545-570. https://doi.org/10.1093/nop/npaf018

Lyu, S., Vaes, R. D. W., Laven, I. E. W. G., Cortiula, F., Hendriks, L. E. L., Vooijs, M. A., & De Ruysscher, D. K. M. (2025). The prognostic and predictive value of peripheral immune-related proteins in patients with lung cancer treated with radiotherapy. Frontiers in Oncology, 15, Article 1625212. https://doi.org/10.3389/fonc.2025.1625212

van Loosbroek, S. Y., Milder, M. T. W., de Ruysscher, D., Vaes, R. D. W., den Toom, W., Willemssen, F., Eskens, F., Homs, M. Y., Groot Koerkamp, B., van Driel, L. M. J. W., Seppenwoolde, Y., van Werkhoven, E., Intven, M., Haj Mohammad, N., de Bruijne, J., Versteijne, E., Bruynzeel, A. M., Brandts, F., Erdmann, J., ... Mendez Romero, A. (2025). STRONG II trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma - a single-arm multicentre phase II study. BMJ Open, 15(7), Article e097545. https://doi.org/10.1136/bmjopen-2024-097545

Puri, T., Rancati, T., Seibold, P., Webb, A., Osorio, E. V., Green, A., Gioscio, E., Azria, D., Farcy-Jacquet, M.-P., Chang-Claude, J., Dunning, A., Lambrecht, M., Avuzzi, B., de Ruysscher, D., Sperk, E., Vega, A., Veldeman, L., Rosenstein, B., Shortall, J., ... REQUITE consortium (2025). Dose-response mapping of bladder and rectum in prostate cancer patients undergoing radiotherapy with and without baseline toxicity correction. Physics & Imaging in Radiation Oncology, 35, Article 100805. https://doi.org/10.1016/j.phro.2025.100805

van Aken, E. S. M., Devnani, B., Castelo-Branco, L., Ruysscher, D. D., Martins-Branco, D., Marijnen, C. A. M., Muoio, B., Belka, C., Lordick, F., Kroeze, S., Pentheroudakis, G., Trapani, D., Ricardi, U., Gandhi, A. K., Prelaj, A., O'Cathail, S. M., & de Jong, M. C. (2025). ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy. Radiotherapy and Oncology, 208, Article 110910. https://doi.org/10.1016/j.radonc.2025.110910